vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and TRIMAS CORP (TRS). Click either name above to swap in a different company.
TRIMAS CORP is the larger business by last-quarter revenue ($256.5M vs $185.2M, roughly 1.4× AMICUS THERAPEUTICS, INC.). TRIMAS CORP runs the higher net margin — 31.9% vs 0.9%, a 30.9% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 3.8%). TRIMAS CORP produced more free cash flow last quarter ($36.8M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 3.3%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Trimas Corp is a diversified industrial manufacturing enterprise that designs, produces and distributes a wide portfolio of engineered products, including specialized fasteners, aerospace components, custom packaging solutions, and consumer & industrial hardware. It primarily serves aerospace, automotive, construction, consumer goods and industrial sectors, with core operations across North America and selected global markets.
FOLD vs TRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $256.5M |
| Net Profit | $1.7M | $81.7M |
| Gross Margin | 85.7% | 12.8% |
| Operating Margin | 8.6% | 5.7% |
| Net Margin | 0.9% | 31.9% |
| Revenue YoY | 23.7% | 3.8% |
| Net Profit YoY | -88.5% | 236.9% |
| EPS (diluted) | $0.00 | $2.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $256.5M | ||
| Q4 25 | $185.2M | $-140.0M | ||
| Q3 25 | $169.1M | $269.3M | ||
| Q2 25 | $154.7M | $274.8M | ||
| Q1 25 | $125.2M | $241.7M | ||
| Q4 24 | $149.7M | $-66.2M | ||
| Q3 24 | $141.5M | $229.4M | ||
| Q2 24 | $126.7M | $240.5M |
| Q1 26 | — | $81.7M | ||
| Q4 25 | $1.7M | $81.7M | ||
| Q3 25 | $17.3M | $9.3M | ||
| Q2 25 | $-24.4M | $16.7M | ||
| Q1 25 | $-21.7M | $12.4M | ||
| Q4 24 | $14.7M | $5.6M | ||
| Q3 24 | $-6.7M | $2.5M | ||
| Q2 24 | $-15.7M | $10.9M |
| Q1 26 | — | 12.8% | ||
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | 12.8% | ||
| Q2 25 | 90.2% | 13.8% | ||
| Q1 25 | 90.7% | 13.6% | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | 15.4% | ||
| Q2 24 | 91.1% | 14.4% |
| Q1 26 | — | 5.7% | ||
| Q4 25 | 8.6% | — | ||
| Q3 25 | 20.3% | 6.2% | ||
| Q2 25 | -6.1% | 9.9% | ||
| Q1 25 | -6.3% | 9.0% | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 15.3% | 3.6% | ||
| Q2 24 | 11.8% | 7.4% |
| Q1 26 | — | 31.9% | ||
| Q4 25 | 0.9% | -58.4% | ||
| Q3 25 | 10.2% | 3.5% | ||
| Q2 25 | -15.8% | 6.1% | ||
| Q1 25 | -17.3% | 5.1% | ||
| Q4 24 | 9.8% | -8.5% | ||
| Q3 24 | -4.8% | 1.1% | ||
| Q2 24 | -12.4% | 4.5% |
| Q1 26 | — | $2.03 | ||
| Q4 25 | $0.00 | $2.01 | ||
| Q3 25 | $0.06 | $0.23 | ||
| Q2 25 | $-0.08 | $0.41 | ||
| Q1 25 | $-0.07 | $0.30 | ||
| Q4 24 | $0.05 | $0.14 | ||
| Q3 24 | $-0.02 | $0.06 | ||
| Q2 24 | $-0.05 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $30.0M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $705.6M |
| Total Assets | $949.9M | $1.5B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $30.0M | ||
| Q4 25 | $293.5M | $30.0M | ||
| Q3 25 | $263.8M | $33.6M | ||
| Q2 25 | $231.0M | $30.3M | ||
| Q1 25 | $250.6M | $32.7M | ||
| Q4 24 | $249.9M | $23.1M | ||
| Q3 24 | $249.8M | $26.9M | ||
| Q2 24 | $260.1M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | $392.7M | $469.2M | ||
| Q3 25 | $392.0M | $407.1M | ||
| Q2 25 | $391.3M | $424.5M | ||
| Q1 25 | $390.7M | $434.2M | ||
| Q4 24 | $390.1M | $398.1M | ||
| Q3 24 | $389.5M | $409.9M | ||
| Q2 24 | $388.9M | $427.4M |
| Q1 26 | — | $705.6M | ||
| Q4 25 | $274.2M | $705.6M | ||
| Q3 25 | $230.4M | $725.0M | ||
| Q2 25 | $204.3M | $715.3M | ||
| Q1 25 | $193.6M | $686.6M | ||
| Q4 24 | $194.0M | $667.3M | ||
| Q3 24 | $178.8M | $682.8M | ||
| Q2 24 | $132.5M | $675.9M |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $949.9M | $1.5B | ||
| Q3 25 | $868.8M | $1.4B | ||
| Q2 25 | $815.3M | $1.4B | ||
| Q1 25 | $789.8M | $1.4B | ||
| Q4 24 | $785.0M | $1.3B | ||
| Q3 24 | $786.6M | $1.4B | ||
| Q2 24 | $749.5M | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 0.66× | ||
| Q3 25 | 1.70× | 0.56× | ||
| Q2 25 | 1.92× | 0.59× | ||
| Q1 25 | 2.02× | 0.63× | ||
| Q4 24 | 2.01× | 0.60× | ||
| Q3 24 | 2.18× | 0.60× | ||
| Q2 24 | 2.93× | 0.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $117.5M |
| Free Cash FlowOCF − Capex | $16.0M | $36.8M |
| FCF MarginFCF / Revenue | 8.6% | 14.4% |
| Capex IntensityCapex / Revenue | 0.2% | 18.9% |
| Cash ConversionOCF / Net Profit | 9.62× | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $109.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $117.5M | ||
| Q4 25 | $16.3M | $41.5M | ||
| Q3 25 | $35.7M | $36.5M | ||
| Q2 25 | $-26.5M | $30.3M | ||
| Q1 25 | $7.8M | $9.2M | ||
| Q4 24 | $-3.9M | $27.1M | ||
| Q3 24 | $-23.0M | $22.0M | ||
| Q2 24 | $22.7M | $18.4M |
| Q1 26 | — | $36.8M | ||
| Q4 25 | $16.0M | $36.8M | ||
| Q3 25 | $35.3M | $22.8M | ||
| Q2 25 | $-28.9M | $13.2M | ||
| Q1 25 | $7.5M | $-3.8M | ||
| Q4 24 | $-4.2M | $12.1M | ||
| Q3 24 | $-23.3M | $10.2M | ||
| Q2 24 | $21.6M | $7.5M |
| Q1 26 | — | 14.4% | ||
| Q4 25 | 8.6% | -26.3% | ||
| Q3 25 | 20.9% | 8.5% | ||
| Q2 25 | -18.7% | 4.8% | ||
| Q1 25 | 6.0% | -1.6% | ||
| Q4 24 | -2.8% | -18.3% | ||
| Q3 24 | -16.5% | 4.4% | ||
| Q2 24 | 17.0% | 3.1% |
| Q1 26 | — | 18.9% | ||
| Q4 25 | 0.2% | -3.4% | ||
| Q3 25 | 0.2% | 5.1% | ||
| Q2 25 | 1.6% | 6.2% | ||
| Q1 25 | 0.2% | 5.4% | ||
| Q4 24 | 0.2% | -22.6% | ||
| Q3 24 | 0.3% | 5.2% | ||
| Q2 24 | 0.9% | 4.5% |
| Q1 26 | — | 1.44× | ||
| Q4 25 | 9.62× | 0.51× | ||
| Q3 25 | 2.06× | 3.92× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | -0.27× | 4.80× | ||
| Q3 24 | — | 8.71× | ||
| Q2 24 | — | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
TRS
Segment breakdown not available.
